Oncology

Low-dose tamoxifen reduces the risk of breast cancer among patients with intraepithelial neoplasia for several years, data suggest.

Ulenistamab targets pancreatic adenocarcinoma upregulated factor, a tumor-specific protein.

Adding vistusertib to treatment with paclitaxel does not improve outcomes in patients with platinum-resistant or -refractory ovarian cancer, a phase 2 trial suggests.

Polypharmacy tied to increased risk for adverse treatment outcomes, such as toxicity and early treatment discontinuation.

FORE8394 is an investigational, novel, small-molecule, next-generation, orally available selective inhibitor of mutated BRAF.

Infections are common among patients with relapsed/refractory multiple myeloma treated with bispecific antibodies, a study suggests.

In subgroup analyses, lower risk was seen with cumulative dosage of 401mg or greater, or with therapy duration of 5 years or longer.

Adding immunotherapy to chemotherapy may increase the risk of toxicity and likelihood of treatment discontinuation in patients with SCLC, a meta-analysis suggests.

This is the first FDA-approved systemic therapy for first-line treatment of pediatric patients with low-grade glioma with a BRAF V600E mutation.

Among older patients with diabetes, metformin was associated with a reduced risk of cancer, but the combination of aspirin and metformin was associated with an increased risk of cancer death.

Catch up on drug news with the latest MPR podcast.

Trend may reflect increasing use of systemic immunotherapies as first-line treatments, according to investigators.

Updated analysis showed longer progression-free and overall survival for patients with advanced renal cell carcinoma

Alisertib monotherapy has shown activity in postmenopausal patients with endocrine-resistant, HER2-negative, metastatic breast cancer, but it was not able to restore sensitivity to fulvestrant in this patient population.

Less high-grade disease recurrence and lower treatment discontinuation seen with gemcitabine and docetaxel versus bacillus Calmette-Guérin

Event-free survival longer for those receiving neoadjuvant and adjuvant pembrolizumab versus adjuvant pembrolizumab only

The panel reviewed data from the randomized, double-blind, placebo-controlled phase 3 POLARIX trial.

Pluvicto is indicated for patients with PSMA-positive metastatic castration-resistant prostate cancer who have been treated with AR pathway inhibition and taxane-based chemotherapy.

Limits on acetaminophen levels in combination opioid products linked to declines in liver injuries; Investigational Alzheimer disease drug fails to show efficacy; Bempedoic acid assessed for reducing major adverse cardiovascular events; Commercial blood test for suspected TBIs; Mammography regulations updated.

The updates require facilities to notify patients regarding the density of their breasts, and strengthen the FDA’s oversight of facilities.